World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
40689
World Ranking
8520
National Ranking
836

Overview

Mark J. Millan is affiliated with the University of Glasgow in the United Kingdom. Their research spans multiple fields with a focus on Medicine, Neuroscience, and Biochemistry, Genetics and Molecular Biology. Within these domains, their work primarily explores Cellular and Molecular Neuroscience, Molecular Biology, Pharmacology, Physiology, and Biochemistry.

The scientist's major topics of study revolve around Receptor Mechanisms and Signaling, Neuroscience and Neuropharmacology Research, and the Treatment of Major Depression. Other notable areas include Alzheimer's disease research and treatments, Neurotransmitter Receptor Influence on Behavior, Tryptophan and brain disorders, as well as Neuropeptides and Animal Physiology.

Notable recent papers authored or coauthored by Millan include:

  • Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action, 2022, Therapeutic Advances in Psychopharmacology
  • Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs, 2020, Neuropharmacology

Other influential works from related fields include "Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing" published in 2020 in Nature Reviews Drug Discovery, and "Prevention of Psychosis" published in 2020 in JAMA Psychiatry.

Frequent coauthors associated with Millan's research include Clotilde Mannoury la Cour, Ross Jeggo, Per Svenningsson, David J. Watson, and K.C.F. Fone, with multiple collaborations ranging from three to four joint publications each.

The scientist regularly publishes in venues such as the International Journal of Molecular Sciences, Neuroscience Applied, Faculty Opinions - Post-Publication Peer Review of the Biomedical Literature, Nature Reviews Drug Discovery, and JAMA Psychiatry.

Best Publications

  • Descending control of pain.

    Mark J. Millan

  • The induction of pain: an integrative review

    Mark J. Millan

  • Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

    Mark J. Millan;Yves Agid;Martin Brüne;Edward T. Bullmore

  • The neurobiology and control of anxious states

    Mark J. Millan

  • Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing

    Stephen C. Cunnane;Eugenia Trushina;Cecilie Morland;Alessandro Prigione

  • Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.

    Mark J. Millan

  • The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

    Mark J. Millan;Alain Gobert;Françoise Lejeune;Anne Dekeyne

  • Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

    Mark J. Millan;Lisa Maiofiss;Didier Cussac;Valérie Audinot

  • Altering the course of schizophrenia: progress and perspectives

    Mark J. Millan;Annie Andrieux;George Bartzokis;Kristin Cadenhead

  • Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.

    Christian de Bodinat;Béatrice Guardiola-Lemaitre;Elisabeth Mocaër;Pierre Renard

  • Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat

    Alain Gobert;Jean‐Michel Rivet;Françoise Lejeune;Adrian Newman‐Tancredi

  • Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing

    Barry Boland;Wai Haung Yu;Olga Corti;Bertrand Mollereau

  • Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention

    Paolo Fusar-Poli;Gonzalo Salazar de Pablo;Gonzalo Salazar de Pablo;Christoph U. Correll;Andreas Meyer-Lindenberg

  • Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors

    Mark J. Millan

  • Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment

    Mark J. Millan;Kevin Fone;Thomas Steckler;William P. Horan

  • Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions.

    Mark J Millan;Philippe Marin;Philippe Marin;Joëel Bockaert;Joëel Bockaert;Clotilde Mannoury la Cour

  • Deconstructing vulnerability for psychosis: Meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk

    P. Fusar-Poli;M. Tantardini;S. De Simone;V. Ramella-Cravaro

  • The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review.

    Mark J. Millan

  • Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

    Mark J. Millan;Mauricette Brocco;Alain Gobert;Anne Dekeyne

  • Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents.

    Mark J. Millan;Françoise Lejeune;Alain Gobert

Frequent Co-Authors

Alain P. Gobert
Alain P. Gobert Vanderbilt University Medical Center
Jean A. Boutin
Jean A. Boutin Institut de Recherches Internationales Servier
Berend Olivier
Berend Olivier Utrecht University
Michael Spedding
Michael Spedding DuPont (United States)
Pierre Sokoloff
Pierre Sokoloff Grenoble Alpes University
Joël Bockaert
Joël Bockaert University of Montpellier
Philippe Marin
Philippe Marin University of Montpellier
Jean-Daniel Brion
Jean-Daniel Brion Centre national de la recherche scientifique, CNRS
Per Svenningsson
Per Svenningsson Karolinska Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medical careers beyond traditional MD programs, a variety of online degrees offer flexible and diverse pathways. Exploring related fields can open doors in healthcare leadership, advanced nursing, and mental health services.

Nurses seeking to specialize in psychiatric care can benefit from online msn pmhnp programs, which prepare graduates for advanced practice roles in mental health. Meanwhile, those interested in the administrative side of healthcare can find rewarding opportunities through healthcare administration degrees. These programs focus on hospital management, policy, and organizational leadership.

Ambitious students looking to advance further may consider a graduate degree, such as the most affordable online mha programs. These programs teach strategic management skills for leading healthcare organizations. For nursing professionals seeking the highest level of clinical expertise, cheap dnp online programs offer a cost-effective way to attain a Doctor of Nursing Practice degree.

Exploring these alternative online degrees can provide more options for entering and advancing in the fast-growing healthcare sector.

Best Scientists Citing Mark J. Millan

Trending Scientists